文献速递头颈与中枢神经肿瘤

世界卫生组织2021年中枢神经系统肿瘤分类及其对成人型胶质瘤治疗的意义:综述

World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
PubMed 文献 · JAMA Oncol · 2022-01-01

该综述阐述了世界卫生组织2021年第五版中枢神经系统肿瘤分类,该分类将组织病理学与分子发病机制结合,首次将成人型和儿童型胶质瘤分开分类,并将成人型弥漫性胶质瘤整合为3种类型。这些由IDH突变状态驱动的重大变化对预后判断和最佳治疗选择具有重要临床意义,并可能促进更有效疗法的开发。

要点

  • 成人型弥漫性胶质瘤被整合为3种类型:星形细胞瘤IDH突变型、少突胶质细胞瘤IDH突变伴1p/19q共缺失型、胶质母细胞瘤IDH野生型。
  • 胶质母细胞瘤的诊断仅限于IDH野生型肿瘤;此前诊断为IDH突变型胶质母细胞瘤的肿瘤被重新分类为星形细胞瘤IDH突变型4级。
  • 分类为星形细胞瘤或少突胶质细胞瘤需要存在IDH突变。

核心结论

  • 2021年世界卫生组织中枢神经系统肿瘤分类是改善脑肿瘤诊断的重大进步,将为临床医生提供更准确的预后和最佳治疗指导,并确保更同质化的患者人群被纳入临床试验,可能促进更有效疗法的开发。

研究设计与样本

  • 本文为综述,阐述2021年世界卫生组织第五版中枢神经系统肿瘤分类及其对成人型胶质瘤治疗的意义。

主要发现

  • 该分类将分子发病机制进展与组织病理学结合,把肿瘤分组为更具生物学和分子学定义的实体,通过更好地表征自然病史显著改进了肿瘤分类。
  • 首次基于分子发病机制和预后的差异将成人型和儿童型胶质瘤分开分类。
  • 此前宽泛的成人型弥漫性胶质瘤类别被整合为3种类型:星形细胞瘤IDH突变型、少突胶质细胞瘤IDH突变伴1p/19q共缺失型、胶质母细胞瘤IDH野生型。

关键数值与推荐

  • 胶质母细胞瘤的诊断仅限于IDH野生型肿瘤。
  • 此前诊断为IDH突变型胶质母细胞瘤的肿瘤被重新分类为星形细胞瘤IDH突变型4级。
  • 分类为星形细胞瘤或少突胶质细胞瘤需要存在IDH突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous histologic classifications of brain tumors have been limited by discrepancies in diagnoses reported by neuropathologists and variability in outcomes and response to therapies. Such diagnostic discrepancies have impaired clinicians' ability to select the most appropriate therapies for patients and have allowed heterogeneous populations of patients to be enrolled in clinical trials, hindering the development of more effective therapies. In adult-type diffuse gliomas, histologic classification has a particularly important effect on clinical care. OBSERVATIONS: In 2021, the World Health Organization published the fifth edition of the Classification of Tumors of the Central Nervous System. This classification incorporates advances in understanding the molecular pathogenesis of brain tumors with histopathology in order to group tumors into more biologically and molecularly defined entities. As such, tumor classification is significantly improved through better characterized natural histories. These changes have particularly important implications for gliomas. For the first time, adult- and pediatric-type gliomas are classified separately on the basis of differences in molecular pathogenesis and prognosis. Furthermore, the previous broad category of adult-type diffuse gliomas has been consolidated into 3 types: astrocytoma, isocitrate dehydrogenase (IDH) mutant; oligodendroglioma, IDH mutant and 1p/19q codeleted; and glioblastoma, IDH wild type. These major changes are driven by IDH mutation status and include the restriction of the diagnosis of glioblastoma to tumors that are IDH wild type; the reclassification of tumors previously diagnosed as IDH-mutated glioblastomas as astrocytomas IDH mutated, grade 4; and the requirement for the presence of IDH mutations to classify tumors as astrocytomas or oligodendrogliomas. CONCLUSIONS AND RELEVANCE: The 2021 World Health Organization central nervous system tumor classification is a major advance toward improving the diagnosis of brain tumors. It will provide clinicians with more accurate guidance on prognosis and optimal therapy for patients and ensure that more homogenous patient populations are enrolled in clinical trials, potentially facilitating the development of more effective therapies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Berger TR, Wen PY, Lang-Orsini M, et al. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review. JAMA Oncol. 2022. PMID: 36006639. doi:10.1001/jamaoncol.2022.2844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。